| Print
Kenvue (KVUE)
Open
$17.80
Previous close
$17.87
Trade high
$17.97
Volume
26,721,865
Year high
$20.13
Year low
$14.02
Dividend yield
4.67%
Market capitalisation
$34.21 bn
P/E ratio
20.95
ISIN
US49177J1025
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Share price
Dividends
| Previous | Latest | |
|---|---|---|
| Record date | 12/08/2026 | 21/09/2026 |
| Ex-dividend date | 12/08/2026 | 21/09/2026 |
| Payment date | 26/08/2026 | 02/10/2026 |
| Amount | $0.21 | $0.21 |
Company profile
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, includingTylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.